Section Arrow
JBIO.NASDAQ
- Jade Biosciences Inc
Quotes are at least 15-min delayed:2026/05/27 04:40 EDT
Pre Market
Last
 21.06
-0.65 (-2.99%)
Bid
8.74
Ask
27
High 21.06 
Low 21.06 
Volume 198 
Regular Hours (Closed)
Last
 21.71
-0.5 (-2.25%)
Day High 
22.81 
Prev. Close
22.21 
1-M High
28 
Volume 
606.40K 
Bid
8.74
Ask
27
Day Low
21.51 
Open
21.55 
1-M Low
20.93 
Market Cap 
1.10B 
Currency 美元 
P/E -- 
%Yield 89.55 
10-SMA 23.55 
20-SMA 24.24 
50-SMA 20.11 
52-W High 28 
52-W Low 6.565 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.63/-2.58
Enterprise Value
1.10B
Balance Sheet
Book Value Per Share
6.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.4002+0.0903+29.14%-- 
Pre Market 0.398 -0.0022 -0.55%
SNGXSoligenix Inc.0.513+0.1229+31.50%-- 
Pre Market 1.075 +0.562 +109.55%
PHGEBiomX Inc.1.62+0.8035+98.41%-- 
Pre Market 1.38 -0.24 -14.81%
RXRXRecursion Pharmaceuticals2.97-0.04-1.33%-- 
Pre Market 2.975 +0.005 +0.17%
ARTLArtelo Biosciences Inc1.71+0.52+43.70%-- 
Pre Market 1.28 -0.43 -25.15%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.